Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss

NCT00925600 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

769

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer
Cataract
Low Bone Mineral Density
Osteopenia
Osteoporosis
Prostate Cancer

Interventions

BIOLOGICAL: Denosumab
BIOLOGICAL: Placebo

Sponsor

Amgen